The present invention provides a therapeutic agent for disc herniation which has extremely few adverse side effects can achieve a prolonged pain ameliorating effect when administered in only a single dose and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1 8 units per disk.
